全文获取类型
收费全文 | 7077篇 |
免费 | 318篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 140篇 |
妇产科学 | 79篇 |
基础医学 | 652篇 |
口腔科学 | 103篇 |
临床医学 | 509篇 |
内科学 | 2153篇 |
皮肤病学 | 99篇 |
神经病学 | 485篇 |
特种医学 | 283篇 |
外科学 | 1345篇 |
综合类 | 28篇 |
预防医学 | 167篇 |
眼科学 | 77篇 |
药学 | 380篇 |
中国医学 | 17篇 |
肿瘤学 | 895篇 |
出版年
2023年 | 50篇 |
2022年 | 98篇 |
2021年 | 186篇 |
2020年 | 91篇 |
2019年 | 125篇 |
2018年 | 169篇 |
2017年 | 127篇 |
2016年 | 155篇 |
2015年 | 168篇 |
2014年 | 225篇 |
2013年 | 277篇 |
2012年 | 447篇 |
2011年 | 460篇 |
2010年 | 281篇 |
2009年 | 189篇 |
2008年 | 379篇 |
2007年 | 440篇 |
2006年 | 409篇 |
2005年 | 443篇 |
2004年 | 480篇 |
2003年 | 467篇 |
2002年 | 423篇 |
2001年 | 107篇 |
2000年 | 96篇 |
1999年 | 94篇 |
1998年 | 99篇 |
1997年 | 89篇 |
1996年 | 69篇 |
1995年 | 56篇 |
1994年 | 57篇 |
1993年 | 47篇 |
1992年 | 57篇 |
1991年 | 45篇 |
1990年 | 48篇 |
1989年 | 59篇 |
1988年 | 53篇 |
1987年 | 51篇 |
1986年 | 33篇 |
1985年 | 33篇 |
1984年 | 19篇 |
1983年 | 21篇 |
1982年 | 15篇 |
1981年 | 15篇 |
1980年 | 18篇 |
1979年 | 23篇 |
1978年 | 18篇 |
1977年 | 20篇 |
1975年 | 17篇 |
1970年 | 12篇 |
1968年 | 14篇 |
排序方式: 共有7445条查询结果,搜索用时 31 毫秒
81.
Yoshie Nakanishi Junichi Kodama Keizo Tokumo Noriko Seki Yasunari Miyagi Mitsuo Yoshinouchi Hiroyuki Okuda Takafumi Kudo 《International journal of clinical oncology / Japan Society of Clinical Oncology》1997,2(4):219-223
Background The object of this study is to clarify the association of an angiogenic factor, PD-ECGF (platelet-derived endothelial cell
growth factor/thymidine phosphorylase), with clinicopathologic factors, in this case tumor angiogenesis, in epithelial ovarian
cancers.
Methods Tumor specimens were obtained at the time of surgery from the primary lesion in 60 patients with epithelial ovarian cancer.
Histologic cell types were assigned to tumors according to the World Health Organization classification: 26 were classified
as serous adenocarcinoma, 15 as endometrioid adenocarcinoma, 9 as mucinous adenocarcinoma, 9 as clear cell carcinoma, and
1 as undifferentiated carcinoma. Surgical staging was based on the international Federation of Gynecology and Obstetrics (FIGO)
staging system: 16 were stage I, 6 were stage II, 34 were stage III, and 4 were stage IV. Expression of PD-ECGF was evaluated
by immunohistochemical staining. Microvessel density was assessed by immunostaining for factor VIII-related antigen in the
most neovascularized area.
Results Stroma cells stained more strongly than cancer cells (80% vs. 33%). The immunopositivity of PD-ECGF in stroma cells was higher
in cases of advanced cancer. Expression of PD-ECGF in mucinous adenocarcinomas was significantly higher than that in serous
adenocarcinomas, while PD-ECGF expression in clear cell carcinomas was significantly lower. The microvessel density in the
cases with marked PD-ECGF-positive stroma cells was significantly higher than that in the cases with absent/minimal PD-ECGF-positive
stroma cells (P<0.05).
Conclusion The expression of PD-ECGF may play a crucial role in the promotion of angiogenesis in epithelial ovarian cancers. 相似文献
82.
Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo 总被引:2,自引:0,他引:2
Yogendra Singh Nobuaki Shikata Yasuhiko Kiyozuka Hiroyuki Nambu Junji Morimoto Junichi Kurebayashi Koshiro Hioki Airo Tsubura 《Breast cancer research and treatment》1997,45(1):15-27
Antitumor and antimetastatic activity of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470), a semisynthetic analogue offumagillin, was evaluated in breast cancer cell lines. In an in vitro MTTassay, after 72 hrs continuous exposure to TNP-470, growth inhibition wasobserved in all seven cell lines of murine (JYG-A, JYG-B, DD-762, andBALB/c-MC) or human (KPL-1, MDA-MB-231, and MKL-F) origin, in which the50% inhibitory concentrations (IC50) at 72 hrstreatment were 4.6, 4.4, 4.6, 10.1, 35.0, 25.3, and 33.4 µg/ml,respectively. In an in vivo assay using JYG-A, JYG-B, KPL-1, and MDA-MB-231cells by orthotopic (right thoracic mammary fat pad) transplantation infemale nude mice, TNP-470 at 30 or 50 mg/kg body weight was injected s.c.every other day from the day of tumor cell inoculation until the end of theexperiment. The inhibitory effect on primary tumor growth was obtained inall four cell lines in a dose-dependent manner. In the 50 mg/kgTNP-470-treated group, the reductions in tumor weight of the JYG-A, JYG-B,KPL-1, and MDA-MB-231 cells with respect to the controls were 50%,30%, 4%, and 49%, respectively. Metastasis was seen inthe JYG-A, JYG-B, and KPL-1 cells. The numbers of mice bearing pulmonarymetastases of JYG-A and JYG-B cells and regional axillary lymph nodemetastases of KPL-1 cells were reduced, and TNP-470 at the 50 mg/kg dose toKPL-1 cells significantly reduced lymph node metastases compared with thecontrol. Although the weight gain was retarded in the TNP-470-treated mice,weight loss was not seen. TNP-470 was highly effective in the treatment ofbreast cancer cells. These results suggest that the clinical use of TNP-470may be a promising treatment for breast cancer patients. 相似文献
83.
Thallium-201 SPECT with triple-headed gamma camera for differential diagnosis of small pulmonary nodular lesion 20 mm in diameter or smaller 总被引:1,自引:0,他引:1
AIM: Although thallium-201 (201Tl) has been used for the diagnosis of lung cancer, its detectability of small pulmonary nodules is not known. The aim of this study was to evaluate the ability of 201Tl SPECT for the differential diagnosis for the pulmonary nodules 20 mm in diameter or smaller. METHODS: 201Tl SPECT was performed in 31 patients suspected of having primary lung cancer. The final diagnosis was established by histology, and tumor size was 10 to 20 mm in diameter. Twenty of 31 patients had malignant tumors, including squamous cell lung cancer (n = 5), adenocarcinoma (n = 14) and small cell lung cancer (n = 1), but in none of them was there mediastinal lymphnode involvement. RESULTS: Ten of 20 malignant tumors and 1 of 11 benign lesions demonstrated significant 201Tl uptake, so that the positive predictive value, negative predictive value, sensitivity and specificity for the diagnosis of lung cancer were 90.9% (10/11), 50.0% (10/20), 50.0% (10/20) and 90.9% (10/11), respectively. CONCLUSION: These data suggest that sensitivity for detecting lung cancer 20 mm or less in diameter may be insufficient, but even in patients with small pulmonary nodules, a positive 201Tl result is highly predictive of lung cancer. 相似文献
84.
85.
Surgery for pulmonary metastases from colorectal carcinoma 总被引:5,自引:0,他引:5
Inoue M Kotake Y Nakagawa K Fujiwara K Fukuhara K Yasumitsu T 《The Annals of thoracic surgery》2000,70(2):380-383
BACKGROUND: This study aims to clarify which patients would benefit by surgery for pulmonary metastases from colorectal carcinoma. METHODS: A retrospective study was undertaken in 25 patients who had undergone complete resection. In all cases, prethoracotomy carcinoembryonic antigen (CEA) level was measured and mediastinal or hilar lymph nodes were histologically examined. RESULTS: Overall 5-year survival was 39.2%. The 5-year survival rate for patients with a normal CEA level was 61.1%, as compared with 19.0% for patients with an elevated CEA level (p = 0.0423). The 5-year survival rate for patients without a lymph node metastasis was 49.5%, as compared with 14.3% for patients with a lymph node metastasis (p = 0.0032). No lymph node metastasis was a predictor of longer survival by univariate and multivariate analyses. The primary site, disease-free interval, and number and size of the metastasis were not significant prognostic factors. CONCLUSIONS: A resection for pulmonary metastasis from colorectal carcinoma is effective in patients with a normal CEA level and without a lymph node metastasis. 相似文献
86.
Takuji Suzuki Tatsuro Fukuhara Masashi Tanaka Akira Nakamura Kenichi Akiyama Tomohiro Sakakibara Daizo Koinuma Toshiaki Kikuchi Ryushi Tazawa Makoto Maemondo Koichi Hagiwara Yasuo Saijo Toshihiro Nukiwa 《Clinical cancer research》2005,11(1):58-66
Cancer immunotherapy by fusion of antigen-presenting cells and tumor cells has been shown to induce potent antitumor immunity. In this study, we characterized syngeneic and allogeneic, murine macrophage/dendritic cell (DC)-cancer fusion cells for the antitumor effects. The results showed the superiority of allogeneic cells as fusion partners in both types of antigen-presenting cells in an in vivo immunotherapy model. A potent induction of tumor-specific CTLs was observed in these immunized conditions. In addition, the immunization with DC-cancer fusion cells was better than that with macrophage-cancer fusion cells. Both syngeneic and allogeneic DC-cancer fusion cells induced higher levels of IFN-gamma production than macrophage-cancer fusion cells. Interestingly, allogeneic DC-cancer fusion cells were superior in that they efficiently induced Th1-type cytokines but not the Th2-type cytokines interleukin (IL)-10 and IL-4, whereas syngeneic DC-cancer fusion cells were powerful inducers of both Th1 and Th2 cytokines. These results suggest that allogeneic DCs are suitable as fusion cells in cancer immunotherapy. To further enhance the antitumor immunity in the clinical setting, we prepared DCs fused with IL-12 gene-transferred cancer cells and thus generated IL-12-secreting DC-cancer fusion cells. Immunization with these gene-modified DC-cancer fusion cells was able to elicit a markedly enhanced antitumor effect in the in vivo therapeutic model. This novel IL-12-producing fusion cell vaccine might be one promising intervention for future cancer immunotherapy. 相似文献
87.
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. 总被引:4,自引:0,他引:4
Toshiya Chiba Koichi Tokuuye Yasushi Matsuzaki Shinji Sugahara Yoshimichi Chuganji Kenji Kagei Junichi Shoda Masaharu Hata Masato Abei Hiroshi Igaki Naomi Tanaka Yasuyuki Akine 《Clinical cancer research》2005,11(10):3799-3805
PURPOSE: We present results of patients with hepatocellular carcinoma (HCC) treated with proton beam therapy. EXPERIMENTAL DESIGN: We reviewed 162 patients having 192 HCCs treated from November 1985 to July 1998 by proton beam therapy with or without transarterial embolization and percutaneous ethanol injection. The patients in the present series were considered unsuitable for surgery for various reasons, including hepatic dysfunction, multiple tumors, recurrence after surgical resection, and concomitant illnesses. The median total dose of proton irradiation was 72 Gy in 16 fractions over 29 days. RESULTS: The overall survival rate for all of the 162 patients was 23.5% at 5 years. The local control rate at 5 years was 86.9% for all 192 tumors among the 162 patients. The degree of impairment of hepatic functions attributable to coexisting liver cirrhosis and the number of tumors in the liver significantly affected patient survival. For 50 patients having least impaired hepatic functions and a solitary tumor, the survival rate at 5 years was 53.5%. The patients had very few acute reactions to treatments and a few late sequelae during and after the treatments. CONCLUSIONS: Proton beam therapy for patients with HCC is effective, safe, well tolerable, and repeatable. It is the useful treatment mode for either cure or palliation for patients with HCC irrespective of tumor size, tumor location in the liver, insufficient feeding of the tumor with arteries, presence of vascular invasion, impaired hepatic functions, and coexisting intercurrent diseases. 相似文献
88.
Kazunori Mawatari Toyohisa Katsumata Masanobu Uematsu Tomoyoshi Katsumata Junichi Yoshida Miro Smriga Takeshi Kimura 《Food and chemical toxicology》2004,42(9):1505-1511
L-leucine, an essential amino acid, is one of the most popular ingredients in dietary supplements. To investigate a possibility of its embryo-fetal toxicity in rats, 11- to 12-week old dams were orally administered an aqueous solution of L-leucine at doses of 300 or 1000 mg/kg body weight on gestational days 7-17. Body weight and feed intake was evaluated throughout the whole course of pregnancy (days 0-20). L-Leucine did not influence body weight, but at a dose of 1000 mg/kg, slightly enhanced feed intake on days 14 and 18 of pregnancy. Caesarean section (day 20) revealed no influences on the litter size and weight of live-born fetuses, the number of corpora lutea, implantation index or the quality of placenta, and the minor increase in feed intake was considered irrelevant to the pregnancy outcomes. Fetuses were evaluated in a battery of external, visceral and skeletal examinations. No effects of L-leucine on gender ratio and external abnormalities, and no significant treatment-related variations in visceral and skeletal pathologies were observed. These results suggested that L-leucine, administered orally during organogenesis at doses up to 1000 mg/kg body weight, did not affect the outcome of pregnancy and did not cause fetotoxicity in rats. 相似文献
89.
Hirokuni Ikeda Naruto Taira Fumikata Hara Takeo Fujita Hiromasa Yamamoto Junichi Soh Shinichi Toyooka Tomohiro Nogami Tadahiko Shien Hiroyoshi Doihara Shinichiro Miyoshi 《Breast cancer research : BCR》2010,12(3):1-12
Introduction
Microtubule-associated protein tau (MAPT) inhibits the function of taxanes and high expression of MAPT decreases the sensitivity to taxanes. The relationship between estrogen receptor (ER) and MAPT in breast cancer is unclear. In this study, we examined the correlation of MAPT expression with the sensitivity of human breast cancer cells to taxanes, and the relationship between ER and MAPT.Methods
The correlation between MAPT expression and sensitivity to taxanes was investigated in 12 human breast cancer cell lines. Alterations in cellular sensitivity to taxanes were evaluated after knockdown of MAPT expression. ER expression was knocked down or stimulated in MAPT- and ER-positive cell lines to examine the relationship between ER and MAPT. The cells were also treated with hormone drugs (tamoxifen and fulvestrant) and taxanes.Results
mRNA expression of MAPT did not correlate with sensitivity to taxanes. However, expression of MAPT protein isoforms of less than 70 kDa was correlated with a low sensitivity to taxanes. Downregulation of MAPT increased cellular sensitivity to taxanes. MAPT protein expression was increased by stimulation with 17-β-estradiol or tamoxifen, but decreased by ER downregulation and by fulvestrant, an ER inhibitor. The combination of fulvestrant with taxanes had a synergistic effect, whereas tamoxifen and taxanes had an antagonistic effect.Conclusions
Expression of MAPT protein isoforms of less than 70 kDa is correlated with a low sensitivity to taxanes in breast cancer cells. ER influences MAPT expression and fulvestrant increases the sensitivity to taxanes in MAPT- and ER-positive breast cancer cells. 相似文献90.
Takayuki Muraoka Junichi Soh Shinichi Toyooka Keisuke Aoe Nobukazu Fujimoto Shinsuke Hashida Yuho Maki Norimitsu Tanaka Kazuhiko Shien Masashi Furukawa Hiromasa Yamamoto Hiroaki Asano Kazunori Tsukuda Takumi Kishimoto Takemi Otsuki Shinichiro Miyoshi 《Lung cancer (Amsterdam, Netherlands)》2013